... therapeutic approach and also examined the performance of the drug cilostazol in triple antiplatelet therapy. The overwhelming conclusion of these studies was that triple antiplatelet therapy for PCI ...
New results suggest that triple antiplatelet therapy for patients undergoing percutaneous coronary intervention with drug-eluting stents achieves greater platelet inhibition than conventional dual ...
... TRIP (aspirin-anticoagulant-antiplatelet) therapy.
Among 78,084 patients, 30.4 ... year of taking these drugs.
"The fact that triple therapy is most commonly prescribed to younger patients reflects ...
... recurrent cardiac ischemia, and other arterial thrombotic events.
"Ticagrelor is the first antiplatelet therapy to achieve a significant reduction in CV mortality in ACS patients versus clopidogrel ...
... growing body of research seeking to evaluate and understand possible sex differences associated with antiplatelet therapies. This study—the first to look at the impact of clopidogrel, one of the most ...
... also limited evidence about the efficacy and safety of other commonly used drugs such as thrombolytic and antiplatelet therapy and devices such as drug-eluting stents, mainly because pregnant patients ...
... infarction. The use of drug-eluting stents necessitates extended treatment with dual antiplatelet therapy (aspirin plus thienopyridine) which may cause bleeding complications and interferes with or ...
... in patients discontinuing dual anti-platelet therapy after only 30 days. The ATLANTA Trial is a first- ... costs associated with long-term dual antiplatelet therapy."
The rapid-exchange, cobalt-chromium ...
... thrombosis (stent-related blood clots) and an associated increased risk of bleeding, due to long-term dual antiplatelet therapy." said Margo Klomp, M.D., first author of ...
... a population level, given how frequently PPI medications are prescribed to patients receiving dual-antiplatelet therapy," the researchers write. "Pending additional evidence, however, the results of ...
... risk of bleeding could receive less aggressive anticoagulant and antiplatelet therapy while those at low risk could receive full-dose therapy."
Led by Sumeet Subherwal, M.D., formerly a ...
... that DES are safe and effective for a wide-range of patients that are able to take dual antiplatelet therapy for at least one year."
The findings were consistent and robust across a variety of study ...
... resources and health care requirements of an ABI screening programme."
The benefits of antiplatelet therapy in the prevention of future cardio- and cerebrovascular events is well established in ...
... the regular use of stents and the routine use of newer adjunctive pharmacotherapy, such as dual antiplatelet therapy and glycoprotein IIb/IIIa inhibitors, both of which have been associated with ...
